Merck Serono's Kuvan Recommended for European Approval
CHMP Issued Positive Opinion Recommending Marketing Authorization of Kuvan(R) for the Treatment of hyperphenylalaninemia in Patients With phenylketonuria or BH4 Deficiency
30-Sep-2008 -
Merck Serono, a division of Merck KGaA announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for hyperphenylalaninemia ...
amino acids
clinical trials
Daiichi Sankyo
+11